GLP-1

Obese man measures his waist
#GlobalData #GLP-1 #Obesity #Phase II trial #Viking Therapeutics #Weight loss

Obesity drug competition expected to intensify by 2030

Viking Therapeutics’ dual GLP-1/GIP receptor agonist VK2735 could become a direct competitor to Eli Lilly’s Mounjaro/Zepbound (tirzepatide), predicts data analytics company GlobalData. In February 2024, Viking Therapeutics published Phase IIa results for its VK2735 candidate, which is being investigated both as a weekly subcutaneous… Read More

#News

Human liver
#Altimmune #GLP-1 #Liver disease #Phase I trial #Weight loss

GLP-1/glucagon receptor agonist shows promise in liver disease

In a 12-week clinical trial, weekly doses of Altimmune’s pemvidutide resulted in up to 68.5% relative reduction in liver fat content (LFC), with up to 55.6% of subjects achieving LFC normalisation after 12 weeks of treatment. The results of the trial, investigating the GLP-1/glucagon dual receptor… Read More

#Editor's Choice #News

Jigsaw puzzle of the brain
#Alzheimer's #Dementia #Diabetes #GLP-1 #Novo Nordisk #Phase II trial #Weight loss

GLP-1 receptor agonist slows Alzheimer’s cognitive decline

In new revelations about glucagon-like peptide-1 (GLP-1) drugs like Ozempic, a study has demonstrated the therapies could protect against dementia. In a Phase IIb trial, Novo Nordisk’s GLP-1 receptor agonist liraglutide appears to reduce shrinking in the parts of the brain that control memory, learning, language… Read More

#News #Trending News

Smoking cessation
#Addiction #Case Western Reserve University School of Medicine #Diabetes #GLP-1 #Nicotine addiction #Smoking cessation #Weight loss

Semaglutide (Ozempic) found to treat smoking addiction

New research has linked semaglutide (the active ingredient in Wegovy and Ozempic) with improved smoking cessation. Rong Xu and colleagues at the Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, US, have reported a reduced desire to smoke in patients… Read More

#News #Trending News

Woman tests blood glucose level
#Clinical trials #Diabetes #GLP-1 #Phesi #Type 2 diabetes

Increase in diabetes research fuelled by GLP-1s like Ozempic

Covid-19 is no longer in the top five most studied indications, replaced by type 2 diabetes, according to Phesi’s mid-year analysis of clinical trials. The analysis of 66,935 clinical trials reveals that the top five most studied diseases are now breast cancer, solid tumours, stroke, prostate… Read More

#News #Trending News

Man wearing a cap mask while sleeping
#American Diabetes Association #Diabetes #Eli Lilly #GLP-1 #Phase III trial #Sleep apnoea #Weight loss

Weight loss drug reduces sleep apnoea severity by 62%

Tirzepatide demonstrated a mean reduction of up to 62.8% on the apnoea-hypopnea index (AHI) compared to placebo in the SURMOUNT-OSA Phase III clinical trials. The drug was tested for the treatment of moderate-to-severe obstructive sleep apnoea (OSA) in adults with obesity, with and without positive airway… Read More

#News #Trending News

#American Diabetes Association #Diabetes #Events #GLP-1 #Obesity #Weight loss

New evidence on GLP-1 receptor agonists at ADA 2024

Further insights on glucagon-like peptide-1 (GLP-1) receptor agonists were presented at the American Diabetes Association (ADA) 84th Scientific Sessions in Orlando, Florida, 21-24 June. Obesity affects 41.9% of adults and 19.7% of children and adolescents in the US, and 90% of people with diabetes also live… Read More

#News #Trending News

#Cardiovascular disease #Diabetes #GLP-1 #UT Southwestern #Weight loss

Data confirms that semaglutide lowers blood pressure

US scientists have released new data supporting initial findings that diabetes and weight loss drug semaglutide (Wegovy/Ozempic) lowers cardiovascular risk regardless of blood sugar. A weekly dose of semaglutide 2.4mg significantly reduced the risk of major adverse cardiovascular events (MACEs) in people with overweight… Read More

#News #Trending News

#Diabetes #GLP-1 #Obesity #Poolbeg Pharma

Removing the needle: the unmet need for oral GLP-1 drugs 

The hormone GLP-1 (glucagon-like peptide-1) and its receptor agonists (GLP-1RAs) have emerged as a compelling class of drugs to tackle diabetes, particularly due to their remarkable efficacy in lowering obesity levels, a fundamental contributing factor of type 2 diabetes. But there is much more to come from this drug class,… Read More

#Exclusive Content #Opinion